What is new are the specific dates (June 2024 injury, November 2024 BPC-157, nothing since), the confirmation that he has stopped TRT and has unused prescription doses sitting at home, and the disclosure that USADA has been in contact
Injection-Based Administration Subcutaneous injections: All GLP-1 RAs are administered via subcutaneous injection Prefilled pens: Most common delivery system, allows for self-administration Auto-injectors: Simplify the process for patients with dexterity issues Multi-dose pens: Require dose dialing and needle attachment Dosing frequency: Daily: Liraglutide (Saxenda, Victoza), some formulations of exenatide (Byetta) Weekly: Semaglutide (Wegovy, Ozempic), tirzepatide (Mounjaro, Zepbound), dulaglutide (Trulicity), exenatide extended-release (Bydureon) Titration schedules: Most FDA-approved GLP-1 RAs require gradual dose escalation to minimize gastrointestinal side effects
Despite this, some clinics administer BPC-157 obtained from research peptide suppliers, offshore pharmacies, or gray-market manufacturers
Potential Clinical Applications of GHK-Cu Peptide Australia Laboratory studies have found that GHK-Cu that GHK-Cu can have the following clinical applications: Enhances Collagen Synthesis According to studies, GHK-Cu activates fibroblasts, the skin cells that produce collagen, which greatly increases collagen production and provides anti-aging advantages
